Tomohiro Sakuma
Papers
1
Total Citations
35
H-Index
1
About
Dr. Tomohiro Sakuma is a leading researcher in pancreatic cancer oncology, with a primary focus on predictive biomarkers and personalized treatment strategies. His most-cited work, a 2010 study on survival prediction for pancreatic cancer patients receiving gemcitabine treatment, has garnered 35 citations and represents a pivotal contribution to the field. In this landmark study, Sakuma employed liquid chromatography-mass spectrometry (LC-MS) to identify novel biomarkers that could forecast patient outcomes, addressing a critical clinical challenge: while gemcitabine remains the standard therapy for advanced pancreatic cancer, patient responses vary widely, and many derive insufficient benefit. By uncovering baseline molecular signatures associated with survival, his research has paved the way for more tailored therapeutic approaches, potentially sparing non-responders from ineffective treatments. This work exemplifies his broader commitment to translating proteomic discoveries into clinically actionable tools. Sakuma’s investigations continue to influence how oncologists stratify patients and optimize chemotherapy regimens, making him a respected voice in the ongoing effort to improve prognosis and quality of life for those battling this devastating disease.
Research Focus
Key Achievements
Top Papers
- 1